https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-non-small-cell-lung-carcinoma-likelihood-of-approval/
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Carcinoma.
osimertinib mesylatesmall celllung carcinomaastrazenecanon